## Research Article

# **Eosinophil Counts in Mucosal Biopsies of the Ileum and Colon: Interobserver Variance Affects Diagnostic Accuracy**

## Florian Hentschel<sup>(D)</sup>,<sup>1</sup> Anna Franziska Jansen,<sup>1</sup> Marlis Günther,<sup>2</sup> Roland Pauli,<sup>2</sup> and Stefan Lüth<sup>1</sup>

<sup>1</sup>Department of Gastroenterology and Hepatology, University Medical Center Brandenburg, Brandenburg, Germany <sup>2</sup>Department of Pathology, University Medical Center Brandenburg, Brandenburg, Germany

Correspondence should be addressed to Florian Hentschel; f.hentschel@klinikum-brandenburg.de

Received 13 September 2018; Accepted 18 October 2018; Published 4 November 2018

Academic Editor: Piero Tosi

Copyright © 2018 Florian Hentschel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Primary eosinophilic gastroenteritis and colitis (EGE) is a rare entity with unspecific clinical and endoscopic findings. Validated histopathologic criteria for confirming the diagnosis are lacking, because numeric values for normal or elevated concentrations of eosinophils in mucosal biopsies are varying between observers. To quantify this interobserver variance, we had the same set of 30 slides of eosinophilic-rich mucosal biopsies from the ileum and colon systematically reviewed by a panel of six independent pathologists, each with more than a ten-year experience in the field. Using a highly standardized biopsy and slide preparation protocol, we ruled out any influence by the preparation, the patient, the endoscopist, the endoscopes and calipers used, the sampling site, the fixation and staining method, and the microscopic field sizes. Still, all numeric results differed between pathologists up to a factor greater than 30. Calculated positive or negative diagnosis of EGE differed up to a factor greater than 8. A theoretical incidence for EGE calculated from these numbers differed by a factor greater than 1500. We conclude that eosinophil counts in mucosal biopsies from the lower gastrointestinal tract are subject to a very high interobserver variance. Until further research provides objective and validated methods for standardization, all epidemiologic numbers derived from histopathologic findings may have to be questioned. When diagnosing individual patients with EGE, overall morphologic picture together with clinical and endoscopic findings is more important than numeric eosinophil count.

## 1. Introduction

Noninfectious, or "primary," eosinophilic gastroenteritis/ colitis (EGE / EC) is a rare entity. For clinical and practical reasons, it is distinguished from the better known eosinophilic esophagitis (EoE), although both are suspected to be caused by  $Th_2$ -mediated food hypersensitivity.

Identifying patients with EGE can be demanding. Clinical symptoms like abdominal pain or recurrent diarrhea are unspecific [1–3]. Endoscopic findings are equally uncharacteristic, often mimicking other diseases [4–6].

Diagnosing EGE/EC therefore strongly relies on histopathologic evaluation of mucosal biopsies. But unlike in the esophagus, where diagnostic criteria for EoE are widely agreed upon [7, 8]; there are no such criteria for the ileum or colon. In normal pediatric mucosa, a wide range between 1 and 52 eosinophils per microscopic high power field (HPF) has been reported. Within this range, some observers saw decreasing eosinophil numbers from the cecum to the sigmoid [9, 10], while others showed an increase from the left colon to the rectosigmoid [11]. Values for adults are roughly within the same range, with superimposed seasonal undulations [12]. For North America, a regional increase from north to south has been reported [11, 13], while in Asia there seems to be no difference according to geographic region, race, or sex [14].

Considering this variance, it is not surprising that there is no consensus about the threshold above which the diagnosis of "eosinophilic ileitis/colitis" can be made. Some authors suggest a value as low as at 6 eosinophils per HPF [15], some 15 to 20 [2, 16], some 30 [17], and some 50 [18]. Recently, a differentiated approach was proposed, with upper limits

University Medical Center Brandenburg Director: Dr. med. Roland Pauli Hochstr. 27 14770 Brandenburg an der Havel **Helios Clinic** Director: Prof. Dr. med. Stefan Koch Pieskower Straße 33 15526 Bad Saarow **Clinical Center Frankfurt** Director: Dr. med. Petra Besuch Müllroser Chaussee 7 15236 Frankfurt (Oder) University Medical Center Ruppin Director: Dr. Frank Lippek Fehrbelliner Straße 38 16816 Neuruppin

Box 1: Institutes of Pathology in Brandenburg that participated in the Study.

from 50 eosinophils per HPF in the right to 25 the left colon [19].

Because of these varying and contradictory numbers (and considering the comparatively clear situation in the esophagus), many authors suspect an undetected bias in the histopathologic findings. Possible confounders like the variability in microscopic HPF size, selection of fields near or far from lymphoid follicles, and differing criteria for including cells in the count had been discussed [20].

To test these hypotheses, we had the same standardized mucosal biopsies from 10 patients examined by six independent specialists in pathology who were blinded for each other's results. Eosinophils were counted according to a standardized protocol, and results were normalized for the HPF areas of the microscopes used.

## 2. Methods

2.1. Patients. We retrospectively examined the histopathologic biopsies of 521 consecutive adult patients who underwent diagnostic ileocolonoscopy in our department from January to December 2017. 84 of them had mucosal biopsies taken because of chronic abdominal pain, recurrent diarrhea, or both. Out of these patients, 10 aroused the clinical or endoscopic suspicion of an elevated eosinophil count in the lower GIT or showed elevated eosinophils in routine histopathologic findings. These were included in the study. Excluded were all patients with inflammatory bowel disease (IBD), collagenous colitis, colonic infections, NSAID treatment, lymphoma, Meniere's disease, and helicobacter pylori infection. All included patients were Caucasians living within < 50 Kilometers from the hospital and prepared for colonoscopy using the same macrogol-based solution (Moviprep, Norgine GmbH, Marburg, Germany).

2.2. Biopsies. All patients were examined by one single endoscopist (F.H.). Two biopsies were taken from 3 standardized locations each (terminal ileum, hepatic flexure, rectum) using 2.3mm calipers (MTW Wolfgang Haag KG, Germany) through flexible colonoscopes (Fujinon EC600, Fuji Corp, Japan). Probes were fixated in 4% buffered formaldehyde (R. Langenbrinck GmbH, Emmendingen, Germany) and brought to the pathologist's laboratory. They were then embedded in 10% paraffin wax (Tissue Tek, Sakura Finetek Europe B.V., Netherlands), cut to  $4\mu$ m slices (Microtome SM2000R/SM2010R, Leica, Germany), and underwent standard H&E staining (Hämalaun Mayer and Hämatoxylin Gill III, Dr. K. Hollborn & Söhne GmbH & Co KG, Germany) in an automated slide stainer and coverslipper (TCA 44-720, MEDITE GmbH, Germany). After routine histopathologic assessment, they were archived.

For the study, original glass slides of included patients were drawn from the archive, anonymized, and sent to the participating pathologists.

2.3. Pathologists and Microscopes. There are six clinical institutes of pathology in the state of Brandenburg. Four of them participated in the study. Mucosal biopsies were examined by six specialists in pathology with at least ten year experience in the field (Box 1), according to standardized counting instructions in German (*for English translation see* Box 2). Microscopes are listed in Table 1. Differing areas of the high power fields (HPF) at 400x magnification were made comparable by a normalization factor, based on current CAP and ITBCC recommendations [23].

2.4. Statistics. All data was analyzed using IBM SPSS Statistics 23. If not stated otherwise, eosinophilic numbers are given as mean +/- standard deviation (SD) out of 5 HPF. For metrically scaled, non-Gaussian data, Friedman test was used for more than two paired samples. Cochran Q Test was used for nominal scaled, paired samples.

#### 3. Results

Eosinophil counts in all biopsies differed between investigators, up to a factor > 30. Maximum count was 328 per HPF (mean of 5, hepatic flexure), and minimum count was 0 per HPF (mean of 5, more than one biopsy site). Analyzing each biopsy site for each patient by investigator, differences between the investigators were significant for all biopsy sites (Table 2, Figures 1(a)–1(c)).

Mean eosinophil counts overall differed between the highest and the lowest counting investigator by a factor of 14.5 (29 vs.2).

Intra-individually, each investigator was concordant to his own bias, i.e. the one with the highest counts overall had those highest counts in all but one biopsy, the one with the lowest count had the lowest count in all but three biopsies (Table 2).

Independently of the strong inter interobserver observer variance, each observer found the highest number of eosinophils in the hepatic flexure, with values between 73 eosinophils per HPF for the highest counting investigator (mean of 5 HPF of all patients), and 5 for the lowest. Numbers in the ileum were intermediate in all investigators with values





(a) Example of eosinophil counts by each investigator (from Table 2). Box plots for 5 HPF from the same single slide of the same patient, normalized (Table 2)

(b) Example of eosinophil counts by each investigator (from Table 2). Box plots for 5 PF from the same single slide of the same patient, normalized (Table 2)



(c) Example of eosinophil counts by each investigator (from Table 2). Box plots for 5 HPF from the same single slide of the same patient, normalized (Table 2)

Figure 1

Intructions for Examination:

- (i) The aim of this study is to count the maximum number of eosinophils per HPF in the ileal, colonic, and rectal mucosa.
- (ii) To do this, identify the 5 HPF with the highest number of eosinophils in every slide, then count the eosinophils in each!
- (iii) HPF must be located > 4 crypts from the next lymph follicle.
- (iv) Do not count intravascular and / or degranulated eosinophils.
- (v) Do count mucosal esoinophils that can clearly be identified by their
- granula, even if their nucleus is out of focus or out of the cutting plane.

Box 2: Instructions for participating pathologists. These instructions follow known procedures in identifying and counting eosinophils in human mucosa [10, 12, 13, 21, 22].

TABLE 1: Microscopes used by the participating pathologists, area of their high power fields (HPF), and normalization factor [23].

Investigator	Microscope	Area HPF (mm <sup>2</sup> )	Normalization Factor		
1	Olympus Bx50 40x/0.65	0.237	1.000		
2	Olympus Bx51 40x/0.75	0.344	0.699		
3	Olympus Bx51 40x/0.75	0.344	0.699		
4	Olympus Bx51 40x/0.75	0.344	0.699		
5	Olympus Bx51 (0.55mm) 40x/0.65	0.237	1.000		
6	Zeiss Axiolab 40x10/0.65	0.331	0.716		

TABLE 2: Eosinophil counts of each pathologist for each anatomic site of each patient. Values shown are mean  $\pm$  SD from 5 HPF and normalized (Table 1). \*Asterisk: Investigator counted 3 HPF as ">100" each, one as 70 and one as 90. p = "asymptotic significance" - Friedman test p-value.

		Inves	stigator 1	Inve	estigator 2	Inve	stigator 3	Inves	tigator 4	Inve	stigator 5	Inve	stigator 6	<i>p</i> Value
Pat 1	Ileum	49	±8,4	4	±1,9	3	±0,7	20	±8,0	5	±1,7	19	±7,2	< 0.001
	Flexure	50	±14,2	10	±4,1	1	±1,1	13	±8,2	4	±1,2	30	±5,5	= 0.001
	Rectum	20	±6,5	5	±1,4	20	±0,5	3	±1,7	2	±1,4	5	±3,1	< 0.001
Pat 2	Ileum	48	±21,1	5	±2,7	7	±3,1	4	±2,6	2	±1,2	24	±11,7	= 0.001
	Flexure	328	±1,4	25	±6,4	13	±1,4	(70)	*	70	±6,3	140	±19,6	< 0.001
	Rectum	78	±12,8	4	±1,2	4	±4,1	20	±14,9	0	±0,4	37	±18,3	< 0.001
Pat 3	Ileum	54	±21,1	5	±4,1	8	±1,4	7	±4,0	2	±0,6	15	±6,5	< 0.001
	Flexure	60	±9,1	8	±1,9	29	±2,0	12	±7,0	4	±1,9	23	±3,2	< 0.001
	Rectum	27	±5,6	5	±1,9	3	±5,2	3	±2,1	1	±1,2	6	±2,9	< 0.001
Pat 4	Ileum	11	±2,7	1	±0,5	6	±1,2	4	±3,0	3	±1,7	4	±1,3	< 0.05
	Flexure	30	±12,8	6	±3,0	1	±2,0	7	±3,6	6	±1,6	22	±6,0	< 0.05
	Rectum	6	±2,2	1	±0,5	3	±0,4	2	±2,7	0	±0,5	3	±1,5	< 0.05
Pat 5	Ileum	89	±14,8	3	±1,2	3	±1,3	6	±1,7	7	±3,1	23	±9,7	= 0.001
	Flexure	42	±13,0	7	±1,4	1	±1,0	6	±2,8	7	±2,5	11	±1,4	= 0.001
	Rectum	7	±3,2	3	±0,9	3	±0,8	1	±1,4	1	±0,9	4	±1,1	< 0.001
Pat 6	Ileum	19	±2,3	4	±2,1	8	±1,7	1	±1,6	0	±0,4	13	±2,3	< 0.001
	Flexure	101	±10,0	13	±5,2	1	±1,7	16	±3,7	4	±2,3	47	±12,6	< 0.001
	Rectum	3	±0,6	2	±1,0	4	±0,5	1	±1,4	1	±0,5	4	±1,5	= 0.001
<b>D</b> :	Ileum	68	±14,4	10	±□3,7	5	±1,8	3	±1,4	1	±0,6	53	±12,1	= 0.001
Pat 7	Flexure	34	±1,4	9	±3,4	2	±1,9	6	±2,9	2	±1,5	29	±6,8	< 0.001
	Rectum	28	±21,1	6	±1,7	2	±0,9	5	±3,9	1	±0,6	5	±2,5	= 0.001
Pat 8	Ileum	31	±6,7	5	±1,0	3	±1,0	4	±2,3	2	±1,1	18	±6,7	= 0.001
	Flexure	34	±8,7	2	±0,6	1	±1,5	6	±3,2	4	±2,0	19	±7,4	= 0.001
	Rectum	7	±3,2	3	±1,0	2	±0,7	6	±2,6	1	±0,5	5	±1,3	= 0.001
Pat 9	Ileum	9	±2,7	3	±1,2	4	±0,7	1	±1,7	1	±0,8	8	±2,5	< 0.001
	Flexure	33	±8,8	6	±1,2	1	±1,2	3	±2,9	2	±0,8	33	±6,3	< 0.001
	Rectum	5	±0,6	2	±1,3	1	±0,5	3	±2,1	0	±0,5	4	±1,0	< 0.05
Pat 10	Ileum	28	±10,1	6	±1,4	3	±1,0	6	±2,2	1	±1,2	11	±10,2	< 0.001
	Flexure	21	±4,6	5	±1,6	1	±0,7	7	±3,4	3	±1,7	8	±2,6	< 0.001
	Rectum	2	±0,4	1	±0,5	3	±0,5	2	±1,0	0	±0,4	1	±0,7	< 0.05



FIGURE 2: Eosinophil numbers in the ileum, hepatic flexure, and rectum by different investigators (Invest. 1 to 6) examining the same 30 slides according to standardized protocol. Numbers are given as means of 5 HPF from 10 patients = 50 HPF, normalized (Table 2).



FIGURE 3: Positive and negative diagnoses for eosinophilic enteritis /colitis by different investigators (Invest. 1 to 6) examining the same 30 slides of 10 patients according to a standardized protocol. Thresholds were Ileum > 20 eosinophiles/HPF, hepatic flexure > 50 eosinophiles/HPF, rectum > 20 eosinophiles/HPF, normalized (Table 2). Results differed significantly (p < 0.05). Changing the thresholds to different values from the literature [9–13] did not change the overall picture (data not shown).

from 41 for the highest counting investigator, and 2 for the lowest. Numbers for the rectum were lowest with numbers from 18 for the highest counting investigator, and 1 for the lowest (Figure 2). Within each investigator, these differences were significant (p < 0.001).

Based on these numbers, we calculated the ratio of positive vs. negative diagnosis for "eosinophilic enterocolitis" for each pathologist, assuming a threshold of 20 eosinophils per HPF in the ileum or rectum and 50 in the hepatic flexure. Results were diverging with observer #1 diagnosing 8 (80%) positive and 2 (20%) negative, while observer #2 diagnosed 0 positive and 10 (100%) negative. Observers #3 and #5

5



FIGURE 4: Virtual incidence numbers of eosinophilic enteritis /colitis in adults calculated for each investigator based on 521 patients scanned for the study. Thresholds for positive diagnosis are > 50 Eosinophils per HPF in the hepatic flexure, and > 20 in the ileum or rectum [9–13].

diagnosed 1 (10%) positive and 8 (90%) negative. Observer #4 diagnosed 2 (20%) positive and 8 (80%) negative. Observer #5 diagnosed 1 (10%) positive and 9 (90%) negative, observer #6 diagnosed 3 (30%) positive and 7 (70%) negative (Figure 3). Cochran Q Test showed these differences to be significant (p < 0.05). Changing the thresholds to different values from the literature did not change the overall picture (data not shown).

Extrapolating from these numbers to the 521 patients who were initially scanned for the study, we calculated a "theoretical overall incidence" for EGE / EC of 1500 per 100,000 for the highest counting investigator, and < 1 per 100,000 for the lowest counting one (Figure 4).

#### 4. Discussion

Eosinophilic diseases of the lower GIT are relatively newly described, incompletely understood, rare, and difficult to detect. Clinical and endoscopic signs are non-specific; histopathologic criteria for mucosal biopsies are lacking. While all authors agree that a certain amount of eosinophils in the ileum and colon is normal, the actual numbers are not known [9–14]. Accordingly, there is no consensus about the limit above which one can safely diagnose an eosinophilic gastroenteritis or enterocolitis. Many authors suggest that the overall morphologic picture together with clinical and endoscopic findings are more important than numeric counts [2, 15, 16, 18, 19, 21]. This is in sharp contrast to the situation in the esophagus, were a number of 16 or more eosinophils per HPF is considered pathognomonic for EoE [7, 8].

Possible explanations for this discrepancy are a lack of clinicopathologic data supporting any particular threshold in the lower GIT, anatomic [9, 10], seasonal [12], genetic or geographic [11, 13] variations in eosinophils, and variations in counting methodology like microscopic field size or criteria of eosinophil counting [20]. Our own suspicion was that numeric eosinophil counts may be observer-dependent.

In this study, we therefore standardized the sampling, processing and examining of 30 slides from ileal, colonic and rectal biopsies from ten Caucasian patients living in the proximity of our center. We then showed the exact same glass slides to six experienced specialists in pathology and asked them to count the eosinophils according to a standardized protocol without knowing the results of each other. Results were normalized to HPF sizes. With this setup, we are confident to have ruled out any influence by the preparation, the patient, the geography, the endoscopist, the endoscopes used, the calipers, biopsy size and number, the topography of the sampling site, the staining method, and the microscopic field sizes. Still, results were strikingly differing.

When discussing this phenomenon with the participating pathologists and gastroenterologists, we did not find an explanation for it right now. One possibility is that the spotty distribution of eosinophils in the lower GIT leads to highly varying concentrations in different HPFs. The error then occurs as early as in the overview, where fields of interest are identified. So, after optical magnification of 400x, every pathologist counts five different regions of the same slide. Further studies, possibly on multiheader microscopes, may be needed to explain these discrepancies. Until then, we can only describe it as extremely high interobserver variance.

Against this background, one may have to rethink some of the facts that are thought to be known about EGE today. Overall prevalence is reported to be about 5 per 100,000 [24, 25], with some observers suggesting it may be higher [17]. One study saw a higher prevalence in male children and female adults [26]: one showed a higher prevalence in Asians [27] and another hinted to a higher incidence in family members of known EGE patients [28]. All of these numbers are derived from histopathologic diagnoses and therefore have to be met with reserve. Extrapolating from our own findings, the true incidence of EGE in our preselected collective could be anywhere between < 1 per 100,000 and 1500 per 100,000.

Since we do not know the exact reason for this phenomenon, we cannot offer a solution right now. Significantly increasing the number of biopsies and HPFs could even out the mean values, but that would be impractical in a real-life clinical situation. Another possibility could be a different staining method to identify and automatically count eosinophils in lower magnification. However, H&E staining that we used is standard for examining mucosal biopsies, and no pathologist reported problems with identifying eosinophils in the slides. So new staining and counting methods would not necessarily be suitable for daily pathologic routine but rather of scientific interest.

#### Abbreviations

- CAP: College of American Pathologists
- EGID: Eosinophilic gastrointestinal disease(s)
- EoE: Eosinophilic esophagitis
- EGE: Eosinophilic gastroenteritis/colitis
- GIT: Gastrointestinal tract
- H&E: Hematoxylin and eosin staining
- HPF: High power field
- IBD: Inflammatory bowel disease
- ITBCC: International Tumor Budding Consensus Conference

Pathology Research International

NSAID: Nonsteroidal anti-inflammatory drug(s) SD: Standard deviation.

#### **Data Availability**

Original slides are archived in the Department of Pathology. Counting protocols are available from author Anna Franziska Jansen.

### **Conflicts of Interest**

All authors declare that there are no conflicts of interest.

## Acknowledgments

Authors Marlis Günther and Roland Pauli were taking part in the study as pathologists. The authors would like to thank the additional pathologists and institutes (see Box 1) who volunteered to examine the slides and Dr. Werner Dammermann for proofreading the manuscript.

## References

- J. R. Guajardo, L. M. Plotnick, J. M. Fende, M. H. Collins, P. E. Putnam, and M. E. Rothenberg, "Eosinophil-associated gastrointestinal disorders: a world-wide-web based registry," *Journal of Pediatrics*, vol. 141, no. 4, pp. 576–581, 2002.
- [2] C. M. Lee, C. S. Changchien, P. C. Chen et al., "Eosinophilic gastroenteritis: 10 years experience," *The American Journal of Gastroenterology*, vol. 88, no. 1, pp. 70–74, 1993.
- [3] W. B. Gaertner, J. E. MacDonald, M. R. Kwaan et al., "Eosinophilic Colitis: University of Minnesota Experience and Literature Review," *Gastroenterology Research and Practice*, vol. 2011, Article ID 857508, 6 pages, 2011.
- [4] A. Llado, J. Oliveira, P. Silva, and S. Pinheiro, "Eosinophilic enteritis: a rare cause of diarrhoea," *BMJ Case Reports*, vol. 2013, no. 1, 2013.
- [5] Y. Kinoshita, K. Furuta, N. Ishimaura et al., "Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis," *Journal of Gastroenterology*, vol. 48, no. 3, pp. 333–339, 2013.
- [6] U. Grzybowska-Chlebowczyk, S. Horowska-Ziaja, M. Kajor, S. Więcek, W. Chlebowczyk, and H. Woś, "Eosinophilic colitis in children," *Advances in Dermatology and Allergology*, vol. 1, pp. 52–59, 2017.
- [7] G. T. Furuta, C. A. Liacouras, and M. H. Collins, "Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment," *Gastroenterology*, vol. 133, no. 4, pp. 1342–1363, 2007.
- [8] A. J. Lucendo, J. Molina-Infante, A. Arias et al., "Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults," *United European Gastroenterology Journal*, vol. 5, no. 3, pp. 335–358, 2017.
- [9] A. Lowichik and A. G. Weinberg, "A quantitative evaluation of mucosal eosinophils in the pediatric gastrointestinal tract," *Modern Pathology*, vol. 9, no. 2, pp. 110–114, 1996.
- [10] C. W. DeBrosse, J. W. Case, P. E. Putnam, M. H. Collins, and M. E. Rothenberg, "Quantity and distribution of eosinophils in the

gastrointestinal tract of children," *Pediatric and Developmental Pathology*, vol. 9, no. 3, pp. 210–218, 2006.

- [11] A. G. Saad, "Normal quantity and distribution of mast cells and eosinophils in the pediatric colon," *Pediatric and Developmental Pathology*, vol. 14, no. 4, pp. 294–300, 2011.
- [12] A. D. Polydorides, B. F. Banner, P. J. Hannaway, and R. K. Yantiss, "Evaluation of site-specific and seasonal variation in colonic mucosal eosinophils," *Human Pathology*, vol. 39, no. 6, pp. 832– 836, 2008.
- [13] R. R. Pascal, T. L. Gramlich, K. M. Parker, and T. S. Gansler, "Geographic variations in eosinophil concentration in normal colonic mucosa," *Modern Pathology*, vol. 10, no. 4, pp. 363–365, 1997.
- [14] T. Matsushita, R. Maruyama, and N. Ishikawa, "The number and distribution of eosinophils in the adult human gastrointestinal tract: a study and comparison of racial and environmental factors," *The American Journal of Surgical Pathology*, vol. 39, no. 4, pp. 521–527, 2015.
- [15] R. D. Odze, J. Bines, A. M. Leichtner, H. Goldman, and D. A. Antonioli, "Allergic proctocolitis in infants: A prospective clinicopathologic biopsy study," *Human Pathology*, vol. 24, no. 6, pp. 668–674, 1993.
- [16] B. M. Yan and E. A. Shaffer, "Primary eosinophilic disorders of the gastrointestinal tract," *Gut*, vol. 58, no. 5, pp. 721–732, 2009.
- [17] K.-K. Abassa, X.-Y. Lin, J.-Y. Xuan, H.-X. Zhou, and Y.-W. Guo, "Diagnosis of eosinophilic gastroenteritis is easily missed," *World Journal of Gastroenterology*, vol. 23, no. 19, pp. 3556–3564, 2017.
- [18] T. Alhmoud, J. A. Hanson, and G. Parasher, "Eosinophilic gastroenteritis: An underdiagnosed condition," *Digestive Diseases* and Sciences, vol. 61, no. 9, pp. 2585–2592, 2016.
- [19] K. O. Turner, R. A. Sinkre, W. L. Neumann, and R. M. Genta, "Primary colonic eosinophilia and eosinophilic colitis in adults," *The American Journal of Surgical Pathology*, vol. 41, no. 2, pp. 225–233, 2017.
- [20] A. W. H. Bates, "Diagnosing eosinophilic colitis: histopathological pattern or nosological entity?" *Scientifica*, vol. 2012, Article ID 682576, 9 pages, 2012.
- [21] N. J. Talley, R. G. Shorter, S. F. Phillips, and A. R. Zinsmeister, "Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues," *Gut*, vol. 31, no. 1, pp. 54–58, 1992.
- [22] T. Lwin, S. D. Melton, and R. M. Genta, "Eosinophilic gastritis: Histopathological characterization and quantification of the normal gastric eosinophil content," *Modern Pathology*, vol. 24, no. 4, pp. 556–563, 2011.
- [23] S. Cho and S. Kakar, "Tumor budding in colorectal carcinoma: translating a morphologic score into clinically meaningful results," *Archives of Pathology & Laboratory Medicine*, vol. 142, no. 8, pp. 952–957, 2018.
- [24] E. T. Jensen, C. F. Martin, M. D. Kappelman, and E. S. Dellon, "Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: Estimates from a national administrative database," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 62, no. 1, pp. 36–42, 2016.
- [25] E. Mansoor, M. A. Saleh, and G. S. Cooper, "Prevalence of eosinophilic gastroenteritis and colitis in a population-based study, from 2012 to 2017," *Clinical Gastroenterology and Hepatology*, vol. 15, no. 11, pp. 1733–1741, 2017.
- [26] C. Reed, J. T. Woosley, and E. S. Dellon, "Clinical characteristics, treatment outcomes, and resource utilization in children and

adults with eosinophilic gastroenteritis," *Digestive and Liver Disease*, vol. 47, no. 3, pp. 197–201, 2015.

- [27] J. Ito, T. Fujiwara, R. Kojima, and I. Nomura, "Racial differences in eosinophilic gastrointestinal disorders among Caucasian and Asian," *Allergology International*, vol. 64, no. 3, pp. 253–259, 2015.
- [28] M. Peršć, T. Štimac, D. Štimac, and D. Kovač, "Eosinophilic colitis: a rare entity," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 32, no. 3, pp. 325-326, 2001.